Factors Tied to COVID-19 Severity, Recovery, and Death in Cancer Patients
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
Diagnosis & Disease Information
Cancer Patients With COVID-19 Less Likely to Receive Critical Care Despite Higher Risk of Death
Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.
COVID-19 Prognosis Improved Over Time for Cancer Patients
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Most Solid Tumor Patients Have ‘Adequate’ Response to COVID-19 Vaccination, Regardless of Treatment
Responses in cancer patients were noninferior to responses in patients without cancer.
Enzalutamide Plus ADT Prolongs Survival in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
Long-Term COVID-19 Symptoms Linked to Treatment, Survival of Cancer Patients
Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.
dd-MVAC Regimen ‘Should Be Gold Standard’ for Muscle-Invasive Bladder Cancer
Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...